Search clinical trials for: 45 mg tolvaptan

Total 10446 results

Avid Radiopharmaceuticals

Terminated

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Alzheimer's Disease

United States
Mayo Clinic
Alexion Pharmaceuticals

Terminated

Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi)

Kidney Transplant

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects

Healthy Adult Male

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)

Carcinomatous Edema

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO 2:4)

Polycystic Kidney, Autosomal Dominant

United States
Duke University

Completed

Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure (TACTICS-HF)

Heart Failure | Dyspnea

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease (ESSENTIAL)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Netherlands
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis

Chronic Renal Failure

Japan
Institute of Liver and Biliary Sciences, India

Recruiting

To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)

Liver Cirrhosis

India
Otsuka Beijing Research Institute

Completed

Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites

Ascites | Hepatic Cirrhosis

China
Texas A&M University

Unknown

Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2

Chronic Obstructive Pulmonary Disease | Muscle Wasting

United States
Sunovion

Completed

Dasotraline SEP360-105 Pediatric PK/PD Study

Pediatric Attention Deficit Hyperactivity Disorder

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Terminated

Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites (ECF)

Hyponatremia and Extracellular Fluid in Cirrhotic

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...
Syneos Health

Terminated

An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

Belgium, Spain, United States, United Kingdom, Italy, Germany, Czechia, Romania
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

Chronic Renal Failure

Japan
Otsuka Pharmaceutical Development & Commercialization...

Withdrawn

A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia

Hyponatremia
University of Michigan
Otsuka Pharmaceuticals

Withdrawn

The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study

Heart Failure

United States
Jiangsu HengRui Medicine Co., Ltd.
Beijing Friendship Hospital; Beijing 302 Hospital; Beijing Anzhen Hospital

Unknown

Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Non-hypovolemic Non-acute Hyponatremia

China
Caleb Nelson
Otsuka America Pharmaceutical

Completed

TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study (TCUPS)

Cystinuria

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Terminated

Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure (AQUATIC)

Heart Failure With Hyponatremia

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia

Hyponatremia
University of Florida
Otsuka America Pharmaceutical

Completed

Tolvaptan for Ascites in Cirrhotic Patients

Cirrhosis | Ascites

United States
Changi General Hospital

Completed

Hypomagnesemia Associated With Proton-Pump Inhibitor Use (PPI_HypoMg)

Arrhythmias, Cardiac | Seizures | Hypocalcemia | Hypokalemia | Hypomagnesemia | Proton Pump Inhibitor Adverse Reaction

Singapore
Seoul National University Hospital

Completed

Passive Leg Raising Test to Predict Hypotension During Induction of Anesthesia in Patients Undergoing Cardiac Surgery

Ischemic Heart Disease | Cardiac Valve Disease

Korea, Republic of
Cephalon

Completed

A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users

Drug Abuse

United States, Canada
Celltrion

Not yet recruiting

A Phase 3 Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

Essential Hypertension
Kyorin University

Unknown

Efficacy of Tolvaptan on ADPKD Patients

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients (INSIGHT)

Hyponatremia

United States
Assiut University

Unknown

Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura

Immune Thrombocytopenia

Egypt
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Tolvaptan in Hyponatremic Cancer Patients

Advanced Cancers

United States
Polderman, Kees, H., MD, PhD
University of Pittsburgh

Terminated

Tolvaptan for Patients With Acute Neurological Injuries

Hyponatremia | SIADH

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema

Cirrhosis

Japan
Otsuka Beijing Research Institute

Completed

Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

Ascites | Hepatic Cirrhosis

China
Genencell Co. Ltd.

Recruiting

Efficacy and Safety of ES16001 in Patients With COVID-19

COVID-19

Korea, Republic of
Nantes University Hospital

Completed

Anti-inflammatory Effect of Serum of Osteoarthritis Patients After Administration of the Oléogrape®SEED, an Extract of Grape and Olive (OléograpeSEED)

Osteoarthritis
Clinique Ovo

Withdrawn

Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization

Women With Fertility Disorder

Canada
Andrew J. Armstrong, MD

Completed

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (CATCH)

Prostate Cancer

United States
Weill Medical College of Cornell University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; University of Sao Paulo and other collaborators

Active, not recruiting

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

HPV Infection | HIV-1-infection | HPV Positive Oropharyngeal Squamous Cell Carcinoma

Brazil, Mexico, Puerto Rico
MedImmune LLC

Completed

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

Healthy Volunteer

United Kingdom
Yungjin Pharm. Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

MELAS Syndrome | Mitochondrial Respiratory Chain Deficiencies

Korea, Republic of
GlaxoSmithKline

Completed

First Time in Human Study Using GSK2330672

Diabetes Mellitus, Type 2

United States
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

Obesity | Overweight
APOGEPHA Arzneimittel GmbH

Completed

Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

Urologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor Function

Romania, Austria, Germany
Mario Negri Institute for Pharmacological Research
A.O. Ospedale Papa Giovanni XXIII

Terminated

Tolvaptan for In-hospital Hyponatremia (INSERT)

Hyponatremia

Italy
Konkuk University Medical Center
Samsung Medical Center; Seoul St. Mary's Hospital; Korea University Anam Hospital and other collaborators

Unknown

Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites (TONIC)

Ascites | Hyponatremia

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Polycystic Kidney Disease, Autosomal Dominant

United States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany
Pfizer

Completed

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Healthy

United States

Search clinical trials for: 45 mg tolvaptan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations